Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-Education Effect on Force Production Capacity After Unilateral Resistance Training in Clinical Populations: A Systematic Review with Meta-analysis.

Sports medicine (Auckland, N.Z.)·2026
Same author

Intracrinology and Testosterone Pellet Therapy: An Enzyme-Aware, Symptom-Driven Approach to Hormone Optimization in Aging.

Cureus·2026
Same author

Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor Expression.

Current oncology (Toronto, Ont.)·2026
Same author

Spatial auditory change detection in listeners with hearing loss.

Hearing research·2026
Same author

Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody-drug conjugate in breast cancer.

Oncology reviews·2026
Same author

The Hippo Pathway in Metaplastic Breast Carcinoma: Prognostic Significance and Therapeutic Implications.

Current issues in molecular biology·2026

Related Experiment Video

Updated: May 25, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Testosterone pellet implants and migraine headaches: a pilot study.

Rebecca Glaser1, Constantine Dimitrakakis, Nancy Trimble

  • 1Millennium Wellness Center, 228 E. Spring Valley Road, Dayton, OH 45458, USA. rglaser@woh.rr.com

Maturitas
|February 8, 2012
PubMed
Summary
This summary is machine-generated.

Continuous testosterone implants significantly reduced migraine severity in 92% of women, regardless of menopausal status. This therapy offered substantial relief, with many reporting no headaches after 3 months.

More Related Videos

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

Related Experiment Videos

Last Updated: May 25, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

Area of Science:

  • Neurology
  • Endocrinology
  • Women's Health

Background:

  • Migraine headaches represent a significant neurological disorder impacting quality of life.
  • Hormonal fluctuations, particularly in women, are often linked to migraine onset and severity.
  • Current treatments for migraine may have limitations or side effects, necessitating exploration of alternative therapies.

Purpose of the Study:

  • To evaluate the efficacy of continuous subcutaneous testosterone implants in mitigating migraine severity.
  • To assess the therapeutic effect of testosterone therapy in both pre- and post-menopausal women experiencing migraines.

Main Methods:

  • Prospective pilot study involving 27 women with a history of diagnosed migraine headaches.
  • Participants rated headache severity on a 5-point scale at baseline and 3 months post-testosterone implant therapy.
  • Comparison of treatment outcomes between pre- and post-menopausal patient groups.

Main Results:

  • A statistically significant improvement in migraine headache severity was observed in 92% of participants.
  • The average improvement in headache severity was 3.3 on a 5-point scale.
  • No significant difference in improvement levels was noted between pre- and post-menopausal cohorts; 74% reported a severity score of '0' (none).

Conclusions:

  • Continuous subcutaneous testosterone implants are an effective therapeutic option for reducing migraine severity in women.
  • Testosterone therapy demonstrates consistent benefits for migraine relief in both pre- and post-menopausal women.
  • Further research is warranted to explore long-term efficacy and optimal dosing of testosterone implants for migraine management.